Inmune Bio (INMB) Short term Debt (2022 - 2024)
Historic Short term Debt for Inmune Bio (INMB) over the last 3 years, with Q3 2024 value amounting to $2.5 million.
- Inmune Bio's Short term Debt fell 7506.0% to $2.5 million in Q3 2024 from the same period last year, while for Sep 2024 it was $2.5 million, marking a year-over-year decrease of 7506.0%. This contributed to the annual value of $9.9 million for FY2023, which is 9842.0% up from last year.
- According to the latest figures from Q3 2024, Inmune Bio's Short term Debt is $2.5 million, which was down 7506.0% from $5.0 million recorded in Q2 2024.
- Inmune Bio's Short term Debt's 5-year high stood at $10.0 million during Q2 2023, with a 5-year trough of $2.5 million in Q3 2024.
- For the 3-year period, Inmune Bio's Short term Debt averaged around $6.6 million, with its median value being $7.5 million (2024).
- Per our database at Business Quant, Inmune Bio's Short term Debt surged by 30000.0% in 2023 and then plummeted by 7506.0% in 2024.
- Quarter analysis of 3 years shows Inmune Bio's Short term Debt stood at $5.0 million in 2022, then soared by 98.42% to $9.9 million in 2023, then tumbled by 74.86% to $2.5 million in 2024.
- Its Short term Debt stands at $2.5 million for Q3 2024, versus $5.0 million for Q2 2024 and $7.5 million for Q1 2024.